Product information
From Health Canada
No match found
No other product was found with the same active ingredient group.
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2024-10-28
Original market date: See footnote 1
2024-10-28
Product name:
IXCHIQ
DIN:
02548984
Product Monograph/Veterinary Labelling:
Date:
2024-06-20
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
VALNEVA AUSTRIA GMBH
Campus Vienna Biocenter 3
Vienna
Wien
Austria
1030
Class:
Human
Dosage form(s):
Powder For Solution
Route(s) of administration:
Intramuscular
Number of active ingredient(s):
1
Schedule(s):
Schedule D
American Hospital Formulary Service (AHFS): See footnote 3
80:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
J07BX OTHER VIRAL VACCINES
Active ingredient group (AIG) number:See footnote5
0165964001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| CHIKUNGUNYA VIRUS LIVE-ATTENUATED | 3 Log10 TCID50 / 0.5 ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.
| Pharmacovigilance/Monitoring Activity |
|---|
| Clinical Trials |
| Observational Studies |